p53 and MDM2 expressionin oral squamous cell carcinoma

Oncology (Switzerland)

Volumn 53, Issue 4, 1996, Pages 308-312

  Matsumura, Tomohiro ^a   Yoshihama, Yasuto ^a   Kimura, Takuji ^a   Shintani, Satoru ^a   Alcalde, Rafael E ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Gene; Immunohistochemistry; Leukoplakia; Oral squamous cell carcinoma; p53 MDM2; Protein

Indexed keywords

GENE PRODUCT; PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MOUTH CANCER; MOUTH MUCOSA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MOUTH NEOPLASMS; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENES; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029882622     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227578     Document Type: Article

References (26)

1. Umckita Y, Kobayashi K, Saheki T, Yoshida H: Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer, Jpn J Cancer Res 1994;85:825-830.
2. Chen C, Oliner JD, Zhan Q, Fornace AJ, Vo-gelstein B Jr, Kastan MB: Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway, Proc Natl Acad Sci USA 1994:91:2684-2688.
3. Fakharzadeh SS, Trusko SP, George DL: Tu-morigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line, EMBO J 1991:10:1565-1569.
4. Lane DP: p53. guardian of the genome, Nature 1992:358:15-16.
5. Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediatcd transactivation, Cell 1992;69:1237-1245.
6. Xiao ZX, Chen J, Levine AJ, Modtahcdi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995.375: 694-698.
7. Goclz SE, Hamilton SR, Vogelstcin B: Purification of DNA from formaldehyde-fixed and paraffin-embedded human tissue, Biochem Biophys ResCommun 1985:130:118-126.
8. Soussi T, Caron dc Fromentel C, May P: Structural aspects of the p53 protein in relation to gene evolution, Oncogene 1990:5:945-952.
9. Anker L, Ohgaki H, Ludeke BI, Herrmann H, Kleihues P, Westphal M: p53 protein accumulation and gene mutations in human glioma cell lines, Int J Cancer 1993;55:982-987.
10. Harlow E, Williamson NM, Ralston R, Helf-man DM, Adams TE: Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol 1985; 5:1601-1610.
11. Sakai E, Tsuchida N: Most human squamous cells in the oral cavity contain mutated p53 tumor-suppressor genes, Oncogene 1992;7: 927-933.
12. Dunn JM, Hastrich DJ, Newcomb P, Maitland NJ, Famdon JR: Correlation between p53 mutations and antibody staining in breast carcinoma, Br J Surg 1993;80:1410-1412.
13. Hall PA, Lane DP: p53 in tumor pathology: Can we trust immunohistochemistry? Revised! J Pathol 1994:172:1-4.
14. Hollstein M, Sidransky D, Vogelstcin B, Harris CC: p53 mutations in human cancer, Science 1991;253:49-53.
15. Nakamura H, Said JW, Miller CW, Koefflcr HP: Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas, Blood 1993:82:920-926.
16. Vogelstein B, Kenneth WK: p53 function and dysfunction, Cell 1992;70:523-526.
17. Fearon ER, Vogelstcin B: A genetic model for colorectal tumorigencsis, Cell 1990:61:759-767.
18. Davidoff AM, Humphrey PA, Iglchart JD, Marks JR: Genetic bases for p53 overexpression in human breast cancer, Proc Natl Acad Sci USA 1991;88:5006-5010.
19. Iggo R, Gattcr K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer, Lancet 1990; 335:675-679.
20. Esrig D, Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen S, Skinner DG, Jones PA, Cote RJ: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer, Am J Pathol 1993;143:1389-1397.
21. Olincr JD, Jinzler KW, Mcltzer PS, George DL, Vogelstein B: Amplification of gene encoding a p53-associatcd protein in human sarcomas, Nature 1992;358:80-83.
22. Shintani S, Yoshihama Y, Alcalde RE, Matsu-mura T: Overexpression of p53 is an early event in the tumorigcnesis of oral squamous cell carcinomas, Anticanccr Res 1995; 15:305-308.
23. Banks L, Matlashewski G, Crawford L: Isolation of human p53-specific monoclonal antibodies and their use in the studies of human TP53 expression, Eur J Biochem 1986:159: 529-534.
24. Yew P, Berk A: Inhibition of p53 transactivation required for transformation by adenovirus early IB protein, Nature 1992;357:82-85.
25. Mietz J, Unger T, Huibrcgtse J, et al: The transcriptional activation function of wild-type TP53 is inhibited by SV 40 large T-antigen and HPV-16 E& oncoprotein, EMBO J 1992:1 1: 5013-5020.
26. Leach FS, Tokino T, Meltzer P, et al: p53 mutation and MDM2 amplification in human soft tissue sarcomas, Cancer Res 1993; 53(suppl):2231-2234.